Partnership with Professor Woei-Jer Chuang of NCKU to explore AI-powered discovery in protein drug design Vizuro Apotek AI Drug Discovery Platform x Industry-Academia Collaboration with NCKU Taipei | [October 27, 2025] — Vizuro LLC, a leading innovator in multimodal causal AI and generative AI for drug discovery, today announced the signing of a Memorandum of Understanding (MOU) with Professor Woei-Jer Chuang, Ph.D., of the Department of Biochemistry and Molecular Biology, Na

Author: Chin-Lin Chen, Ph.D / Data Scientist at Vizuro Key Takeaway Drug discovery has entered the era of big data. Every year, thousands of disease and normal samples are profiled — yet one critical bottleneck remains: identifying clinically meaningful target–marker gene pairs for new drug development . The core value of Apotek Path is for this purpose: Identify disease-relevant targets → Causal modeling reveals mechanistic gene interactions tailored to your disease contex

Why causal AI is becoming pharma’s next strategic differentiator — from target validation to clinical trials and real-world evidence....

Fig 1.  Adaptyv Bio “Protein Design Competition Round2” Competition Overview Protein binding remains one of the most challenging aspects...

Key Takeaways: The 2024 Nobel Prize in Chemistry was awarded for groundbreaking advancements in computational protein structure...